Myrexis, Inc. (MYRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
305 CHIPETA WAY SALT LAKE CITY, UT 84108 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2013 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | |||
| Cash and cash equivalents | |||
| Short-term investments | |||
| Other undisclosed current assets | |||
| Total current assets: | |||
| Noncurrent Assets | |||
| TOTAL ASSETS: | |||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | |||
| Accrued liabilities | |||
| Total current liabilities: | |||
| Noncurrent Liabilities | |||
| Total liabilities: | |||
| Equity | |||
| Equity, attributable to parent | |||
| Common stock | |||
| Additional paid in capital | |||
| Accumulated deficit | |||
| Total equity: | |||
| TOTAL LIABILITIES AND EQUITY: | |||
Income Statement (P&L) (USD)
| 6/30/2013 | ||
|---|---|---|
| Operating expenses | ||
| Other undisclosed operating income | ||
| Operating loss: | ||
| Nonoperating income | ||
| Investment income, nonoperating | ||
| Other nonoperating income | ||
| Loss from continuing operations: | ||
| Loss before gain (loss) on sale of properties: | ||
| Net loss: | ||
| Other undisclosed net loss attributable to parent | ||
| Net loss available to common stockholders, diluted: | ||
Comprehensive Income (USD)
| 6/30/2013 | ||
|---|---|---|
| Net loss: | ||
| Comprehensive loss: | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | ||
| Comprehensive loss, net of tax, attributable to parent: | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.